Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

Pages

1472 results
8:19 AM, Sep 14, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

CARsgen solid tumor CAR T leads to complete response

member 17; TNFRSF17; CD269) for multiple myeloma, CD19 for B cell leukemia and lymphoma, EGFR/epidermal growth factor
10:24 AM, Aug 17, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

pain caused by osteoarthritis of the knee or hip. Fasinumab is a mAb against nerve growth factor
Israel  Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan  Product: Fasinumab  Business: Neurology  Molecular target: Nerve growth factor
8:15 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

RegenxBio's AMD gene therapy well tolerated in Phase I

RegenxBio Inc. (NASDAQ:RGNX) said a single subretinal injection of RGX-314 was well tolerated with no treatment-related serious adverse events reported in a Phase I trial to treat wet age-related macular degeneration (AMD). RGX-314 is an...
8:14 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

last follow-up visit by 6.9%. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor
CTGF). RXi Pharmaceuticals Corp. (NASDAQ:RXII), Marlborough, Mass.  Product: RXI-109  Business: Ophthalmic  Molecular target: Connective tissue growth factor
8:12 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Genentech reports Phase II data for sustained delivery eye implant of ranibizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said the majority of patients who received Port Delivery System (PDS) administration of ranibizumab were able to go six months or longer between implantation and the first...
10:21 AM, Jul 27, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Takeda's Alunbrig meets in Phase III for first-line NSCLC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said first-line treatment with Alunbrig brigatinib met the primary endpoint of improving independent review committee (IRC)-assessed progression-free survival (PFS) vs. Xalkori crizotinib in the Phase III ALTA-1L trial to treat...
9:19 AM, Jul 20, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Pfizer's tanezumab meets in Phase III for OA pain

osteoarthritis pain. Pfizer said the data support the use of the humanized mAb against nerve growth factor
Indianapolis, Ind.  Pfizer Inc. (NYSE:PFE), New York, N.Y.  Product: Tanezumab  Business: Neurology  Molecular target: Nerve growth factor
9:02 AM, Jul 20, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Allergan's abicipar pegol non-inferior to Lucentis, but increases inflammation

Allergan plc (NYSE:AGN) and Molecular Partners AG (SIX:MOLN) said both dosing regimens of abicipar pegol (AGN-150998) met the primary endpoint of non-inferiority to Lucentis ranibizumab in the proportion of patients with stable vision at week...
12:24 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Acceleron, Celgene score second win with latest luspatercept readout

modified activin receptor type 2B (ACVR2B) fusion protein that inhibits several ligands in the transforming growth factor
type 2B (ACVR2B)  Description: Modified ACVR2B fusion protein that inhibits several ligands in the transforming growth factor
12:18 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Merck KGaA reports Phase I response data for M7824 in HPV-associated cancer

patients. The primary endpoint is ORR. M7824 is a fusion protein targeting PD-L1 and transforming growth factor
Germany  Product: M7824  Business: Cancer  Molecular target: PD-L1  Description: Fusion protein targeting PD-L1 and transforming growth factor

Pages